Dare Bioscience (NASDAQ:DARE) Posts Earnings Results, Beats Estimates By $0.10 EPS

Dare Bioscience (NASDAQ:DARE) announced its quarterly earnings results on Thursday. The biotechnology company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.10, Zacks reports. The business had revenue of $0.19 million during the quarter, compared to analysts’ expectations of $0.00 million. Dare Bioscience had a negative return on equity of 512.31% and a negative net margin of 803.80%.

Here are the key takeaways from Dare Bioscience’s conference call:

• Commercialization has begun with Flora Sync LF5 launched in June and DARE to PLAY sildenafil cream expected to begin prescription dispensing in the third quarter, creating initial product revenue opportunities.
• Daré is building a multi-product commercial platform through its DARE Health Hub, provider relationships, telehealth partnerships, and digital marketing, with management targeting stronger, more efficient growth in 2027 and beyond.
• The pipeline advanced, including positive interim safety results for the pivotal Ovaprene contraceptive study, initiation of a phase II DARE-HPV trial, and an additional $1 million NIAID funding award that brings total DARE-HPV project funding to $2 million.
• Financial resources remain limited, with approximately $12.6 million in cash, a $0.2 million working-capital deficit, and only about $0.2 million in second-quarter revenue; Flora Sync sales were not reflected until July.
• Although the FDA approved an Ovaprene protocol amendment removing the requirement for 250 completers, it strongly recommended maintaining that target and indicated it may be necessary to adequately characterize safety, creating potential regulatory and timeline risk.

Dare Bioscience Trading Down 32.1%

Shares of NASDAQ DARE traded down $0.44 during trading on Friday, reaching $0.93. The company had a trading volume of 8,003,967 shares, compared to its average volume of 502,329. Dare Bioscience has a twelve month low of $0.77 and a twelve month high of $3.78. The stock has a 50-day moving average price of $1.74 and a two-hundred day moving average price of $1.88. The stock has a market capitalization of $14.02 million, a PE ratio of -1.33 and a beta of 1.08.

Wall Street Analyst Weigh In

DARE has been the topic of a number of research reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Dare Bioscience in a research note on Friday, July 17th. Wall Street Zen upgraded shares of Dare Bioscience to a “hold” rating in a research report on Saturday, May 23rd. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $10.00.

Institutional Trading of Dare Bioscience

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DARE. LPL Financial LLC acquired a new position in Dare Bioscience in the 4th quarter valued at about $28,000. Raymond James Financial Inc. lifted its holdings in Dare Bioscience by 810.6% in the 3rd quarter. Raymond James Financial Inc. now owns 15,334 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 13,650 shares in the last quarter. Finally, Virtu Financial LLC acquired a new stake in shares of Dare Bioscience during the 3rd quarter worth about $37,000. Hedge funds and other institutional investors own 6.70% of the company’s stock.

Dare Bioscience Company Profile

Dare Bioscience, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for women’s reproductive health. The company’s flagship development candidate is Ovaprene, a monthly, self-administered, non-hormonal contraceptive vaginal ring designed to offer an alternative to traditional hormone-based birth control methods. Through its proprietary intravaginal drug delivery platform, Dare seeks to address unmet medical needs in gynecology and contraception with products that prioritize efficacy, safety and ease of use.

In addition to its lead contraceptive program, Dare is advancing a pipeline of early-stage assets aimed at treating gynecologic conditions through local, non-systemic drug delivery.